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Abstract
Our previous studies have shown that subthreshold
concentrations of two platelet agonists exert syner-
gistic effects on platelet aggregation. Here we studied
the mechanism of synergistic interaction of 5-
h y d r o x y -tryptamine (5-HT) and epinephrine
mediated platelet aggregation. We show that 5-HT
had no or little effect on aggregation but it did
potentiate the aggregation response of epinephrine.
The synergistic interaction of 5-HT (1-5 M) and
epinephrine (0.5-2 M) was inhibited by 2-
adrenoceptor blocker (yohimbine; IC5 0= 0.4 M ) ,
calcium channel blockers (verapamil and diltiazem
with IC5 0 of 10 and 48 mM, respectively), P L C
inhibitor (U73122; IC5 0=6 M) and nitric oxide (NO)
d o n o r, SNAP (IC5 0=1.6 M)). The data suggest t h a t
synergistic effects of platelet agonists are recep-tor-
mediated and occur through multiple signalling
pathways including the activation PLC/Ca2 + s i g n a l l i n g
cascades.
K e y w o r d s : platelet Aggregation, phospholipase C, calcium
channel blockers, epinephrine, 5-hydroxytryptamine
Introduction
Platelets react rapidly with a wide range of agonists to
maintain vascular integrity and haemostasis. Upon
vascular damage, platelets undergo rapid transformation;
become more spherical, extrude pseudopodia and
activate their fibrinogen receptors leading to aggregation.
During this activation process, platelets release granule
contents and substances which act in autocrine fashion
to further enhance aggregation and haemostasis (Siess,
1989; Brass et al., 1993). The platelet agonists act in
synergy to potentiate each other’s effect (Ware et al. ,
1987).
Most of the platelet agonists, like thrombin, ADP,
PA F, epinephrine and 5-HT, interact with their
transmembrane receptors on platelets coupled with GTP
binding proteins (G proteins). The G-proteins mediate a
variety of cellular processes by activating diff e r e n t
e ffector molecules, in-cluding adenylyl cyclase, inositol
phospholipid-specific phospholipase C (PLC) or ion
channels (Siess et al., 1989; Exton, 1996). In human
platelets, activation of Gs/adenylyl cyclase decreases
platelet aggregation. In contrast, acti-vation of
Gi/adenylyl cyclase (e.g. by epinephrine) leads
decreases intracellular cAMP levels and increases platelet
aggregation (Siess et al., 1989). In platelets, stimulation
of receptors coupled with phosphoinositidase C-linked
G-proteins (Gq) (e.g., by 5-HT, PAF or thrombin) leads
to activation of PLC and thus generation of second
messengers, diacylglycerol (DAG) and inositol-1,4,5-
triphosphate (IP3). This results in the activation of protein
kinase C (PKC) and the mobilization of intracellular Ca2 +,
respectively [Obberghen-Schilling and Pouyssegur, 1993).
Both Ca2+ and PKC act in synergy to enhance (Crabos
et al ., 1992) whereas deficiency of Gq protein leads to
impairment of platelet aggregation (Offermans et al. ,
1997).
We and others have shown that subthreshold con-
centrations of platelet agonists potentiate aggregation
response and thus exhibit synergistic effects (Ware et al.,
1987; Saeed et al., 1997). This synergism is considered
to occur mainly through priming of Ca2+ responses, but
the role of other effectors and second messengers is
not well known. Here we show that synergistic inetraction
of 5-HT and epinephrine can be inhibited by Ca2 +- c h a n n e l
blockers and PLC inhibitor suggesting the involvement
of calcium and Gq/PLC pathways in this cascade.
Materials and Methods
Chemicals
Epinephrine, 5-HT, diltiazem, verapamil and yohimbine
were purchased from the Sigma Chemical Co. (St. Louis,
MO. USA). U73122 and SNAP were from Alexis LC.
Labs (UK). Antisera to various G proteins were kind gift
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from Professor Graeme Milligan (Glasgow, UK). All
other chemicals were of the highest purity grade
available.
Preparation of human platelets 
Blood was taken by veinpuncture from normal human
volunteers reported to be free of medication for one week.
Blood samples were mixed with 3.8% (w/v) sodium
citrate solution (9:1) and centrifuged at 260 g for 15 min
at 20˚C to obtain platelet rich plasma (PRP) with platelet
counts between 2.5 and 3✕1 08/ml of plasma. All
experiments were performed within 2 h of PRP
preparation.
Measurement of platelet aggregation
Aggregation was monitored using a Dual-channel Lumi-
aggregometer (Model 400 Chronolog Corporation, Chicago,
U.S.A.) using 0.45 ml aliquots of PRP (Shah and Saeed,
1995). The final volume was made up to 0.5 ml with test
drug dissolved either in normal saline or appropriate
vehicle known to be devoid of any effect on
aggregation. Aggregation was induced with epinephrine
and sub-threshold concentration determined. To obtain
the syner-gistic effect of 5-HT and epinephrine, we
added low concentrations of these agonists together.
The anti-aggregatory effects were studied by
pretreatment of PRP with various inhibitors for one
minute fol lowed by addit ion of the subthreshold
concentrations of epinephrine and 5-HT. The resulting
aggregation was recorded for 5 min after challenge by
the change in light transmission as a function of time.
Once the anti-platelet activity of various inhibitors
against agonists was established, dose-res-ponse
curves were constructed to calculate the IC50 values of
the test substances. Statistical analysis was done using
Student’s t-test.
Western blots 
The generation and specifities of the various antisera
used in this study are already described (Mitchell et al.,
1991). Membrane samples were resolved by SDS/PA G E
in 10% (w/v) acrylamide gels overnight at 60 V. For
resolving Gqa and G11a, urea linear gradient gels were
prepared and run overnight at 100 V as described in
detail previously (Shah and Milligan, 1994). Proteins
were transferred to nitrocellulose (Schleicher and
Schuell) and blocked for 3 h in 5% (w/v) gelatin in
phosphate buffered saline (PBS), pH 7.5. Primary
antisera were added in 1% gelatin in PBS containing
0.2% Nonidet P-40 (NP-40) and incubated overnight.
The primary antiserum was removed and blots washed
extensively with PBS containing 0.2% NP-40. Secondary
antiserum (donkey anti-rabbit IgG coupled to
horseradish peroxidase; HRP) in 1% g e l a t i n / P B S / 0 . 2 %
NP-40 was added and left for 3h. After removal of the
second antiserum, blots were washed extensively as
above and developed with o-dianisidine hydrochloride
as substrate for HRP. 
Results and Discussion
Platelet membranes were subjected to immunoblot analysis
using antisera specific against the α-subunit of Gs, Gi
and Gq/11 proteins. Western blots results in Figure 1A
show that human platelets express predominantly 45 kD
adenylyl cyclase-stimulatory G protein (GSα) as well as
inhibitory (Gi2) G proteins. Using urea gradient g e l s
under the conditions where Gqα and G11α proteins can
be separated and detected by CQ2 antisera (Shah and
Milligan, 1994), we find that platelets contain only G qα
protein (42 kD) but not G11a (Figure 1B). Normally Gqα
and G11α are co-expressed in most of the body tissues
(Mitchell et al., 1991; Shah and Milligan, 1994).
Treatment of PRP with 5-HT up to 10 μM had no
appreciable effect on platelet aggregation, however,
Figure 1. Immunoblot analysis of G proteins in membranes prepared from human
platelets. (A): Detection of α-subunit of Gs and Gi proteins. (B): Detection of Gqα and
G11α proteins after their separation by urea gradient gels. The antiserum CQ2
recognizes α-subunit of both Gqα and G11α proteins (Shah and Milligan, 1994).
Platelets express only Gqα protein (lane 1) compared to both Gqα and G11α in
other body tissues. Lane 2 shows Gqα and G11α in pituitary gonadotrophs.
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Figure 2. Effect of various inhibitors on
platelet aggregation mediated by synergistic
interaction of 5-HT and epinephrine. (A)
Data from a representative experiment
showing synergism of 5-HT (2 μM) and
epinephrine (1 μM) which is inhibited by
yohimbine (B), verapamil (C) and U73122
(D). Control means platelet aggregation
induced by 5-HT (1-2 μM) plus epinephrine
(0.5-2 μM).
Figure 3. Dose-response inhibitory effect of NO donor, SNAP and phospholipase C
inhibitor, U73122 on platelet aggregation induced by subthreshold concentrations of 5-
HT (1-2 μM) and epinephrine (0.5-2 μM). Data is mean ± SEM (n=6). Both U73122
(2-16 μM) and SNAP (0.1-4 μM) showed dose-dependent significant inhibitory effect
on aggregation.
Figure 4. A model depicting the role of Gq and Gi proteins during co-activation by 5-HT
and epinephrine (Epi). The Gqα and Giβ γ subunits converge at phospholipase C
(PLC), which leads to generation of inositol triphosphate (IP3) and diacylglycerol (DAG)
and thus release of Ca2 + from internal stores and activation of protein kinase C (PKC).
Both Ca2 + and PKC are considered to be involved in the release of granule contents and
activation of phospholipase A2, thus generation of potent agonist, thromboxane A2
( T X A2) which in an autocrine fashion acts on platelets through Gq protein. Also Epi-
mediated decrease in cAMP levels stimulate aggregation. NO from exogenously added
SNAP (NO donor) inhibits platelet aggregation through production of cGMP from
guanylate cyclase. The cGMP activates PKG which can phosphorylate PLC, Ca2 +-
channels or IP3-receptor to inhibit Ca2 +-mediated pro-aggregatory effects in platelets.
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epinephrine (0.2-20 μM) had concentration-dependent
increase in platelet aggregation. The simultaneous
addition of subthreshold concentrations of 5-HT (1-2
μM) and epinephrine (0.5-1 μM) exhibited synergistic
e ffect (Figure 2A). 5-HT is considered a weak platelet
agonist as it causes only shape change in platelets (Steen
et al., 1993), however, subthreshold concentrations of
5-HT and epinephrine, when used together, can elicit a
strong synergistic effect on platelet aggregation. Such a
mechanism of synergism is known among other agonists
too and is considered to occur due to activation of Ca2+
signalling cascade. It has been reported that a rise in Ca2 +
induced by first agonist primes platelets for an enhanced
functional response to the second agonist (Ware et al .,
1987). Results show that the synergism between 5-HT
and epinephrine is inhibited by pretreatment of PRP with
yohimbine indicating that the effect is mediated through
α2-adrenoceptors (Figure 2B). The half-maximal inhibitory
concentration (IC5 0) of yohimbine against 5-HT plus
epinpehrine was 0.4 μM.
Receptors for 5-HT in platelets are coupled with Gq/
PLC (De Chaffoy de Courcelles et al., 1987; Martin, 1994)
whereas epinephrine interacts with α2- a d r e n o c e p t o r s
coupled with Gi/adenylyl cyclase pathway (Steen et al .,
1993). Recent studies show that β γ-subunits of activated
Gi protein can also activate PLC (Clapham and Neer,
1997; Banno et al., 1998). We used PLC inhibitor (U73122)
to examine if 5-HT and epinephrine mediated eff e c t s
involved PLC. Results show that pretreatment of PRP
with U73122 inhibits the platelet aggregation mediated
by synergistic effect of 5-HT and epinephrine (Figure
2D). The IC5 0 of U73122 was 6 μM (Figure 3). This
raises the possibility of convergence of Gi and Gq
pathways at PLC during platelet aggregation. A similar
phenomenon has been observed in HEK 293 cells
where it is shown that G β γ subunit-mediated α2-
adrenoceptor and Gq/11 mediated α1 B- a d r e n o c e p t o r -
coupled MAP kinase path-ways converge at the level of
PLC (Della Rocca et al., 1997). In fact the βγ-subunits of
Gi2 and Gq proteins have similar efficacy in regulation
of effector (PLC) in human platelets (Banno et al. ,
1998).
Since activation of Gq/PLC pathway leads to an
increase in cytosolic Ca2 + due to its release from internal
stores by IP3 or through store-depleted calcium influx
(Berridge, 1993; Heemskerk and Sage, 1994), we used
Ca2+ channel blockers (verapamil and diltiazem) to see
if the Ca2+ signalling is involved in aggregation following
co-activation by 5-HT and epinephrine. We found that
the synergistic effect of 5-HT and epinephrine is inhibited
by both verapamil (IC5 0= 10 μM, Figure 2C) and diltiazem
(IC50= 48 μM, Table 1). Verapamil has been shown to
inhibit platelet aggregation, Ca2 + fluxes and thromboxane
production induced by ADP, collagen and thrombin
(Brocchieri et al., 1995; Saeed et al., 1997). It is well
known that Ca2 + plays pivotal role in platelet aggregation
(Heemskerk and Sage, 1994; Shah et al., 1996, 1998).
A rise in cytosolic Ca2 + levels accompanies platelet
activation through stimulation of the enzymes which are
not fully functional at low Ca2+ concentration present in
the resting platelets (Heemskerk and Sage, 1994). Inter-
ruption in the process of Ca2+ activation either through
C a2 +-channels (Brocchieri et al., 1995; Shah et al., 1997)
or Gi/Gq proteins (Offermans et al., 1997) can interfere
in the activation of platelets. 
Previously it was shown that cyclic nucleotides, cAMP
and cGMP through activation of cAMP- and cGMP-
d e p e n -dent protein kinase, down-regulate the Ca2 +
responses and thus inhibit platelet aggregation. We tested
if increasing intracellular nitric oxide (NO) levels by NO
donor (SNAP) and thus activating cGMP kinase has any
inhibitory effect on platelet aggregation induced by
epinephrine and 5-HT. Results show that SNAP inhibits
platelet aggregation at very low concentrations (IC5 0;
1.6 μM) suggesting that epinephrine and 5-HT
synergism is sensitive to NO generation (Figure 3). In
fact platelets contain an abun-dance of cAMP and
cGMP-dependent protein kinases (El-Daher, et al . ,
1996) which can inhibit PLC-induced inositol phosphate
production and inactivate IP 3 and thromboxane
receptors (see review by Heemskerk and Sage, 1994;
Wa n g et. al . ,  1998), thus inhibi t ing the platelet
aggregation.
Multiple studies have shown that agents (like epine-
phrine) which decrease intracellular cAMP levels stimulate
platelet aggregation (Brass et al., 1993; Siess et al., 1993).
In fact epinephrine effects in platelets may involve multiple
signalling pathways; stimulation of IP3 production through
stimulation of PLC by G protein β γ-subunits (Clapham
and Neer, 1997; Banno et al ., 1998), increase in Ca2+-
influx, thus activation of phospholipase A2 (Heemskerk
and Sage, 1994) and activation of some other proteins
like Syk (Wang et al ., 1997). In conclusion, our results
point to a new facet of 5-HT and epinephrine synergistic
interaction and further demonstrate that such an effect
is receptor mediated and occurs due to activation of Gq
and Gi proteins which converge at PLC and Ca2 + s i g -
nalling pathways as depicted in Figure 4. 
Table 1. Effect of various inhibitors on platelet aggregation mediated by synergistic
interaction of 5-HT (1-5 μM) and epinephrine (0.5-2 μM). Data is mean ± SEM (n=6-
7) and is indicated as half-maximal effect (IC50) of inhibitors. 
Inhibitor IC50 of inhibitor (mM)
Yohimbine 0.4 ± 0.06
Verapamil 10    ± 2
Diltiazem 48    ± 8
U73122 6    ± 0.8
SNAP 1.6 ± 0.02
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